Patel Sneha, Kumthekar Anand
Rheumatology, Acclaim Physicians/JPS Hospital, Fort Worth, TX, USA.
Division of Rheumatology, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY, USA.
Rheumatol Ther. 2022 Feb;9(1):49-71. doi: 10.1007/s40744-021-00397-7. Epub 2021 Nov 19.
Psoriatic arthritis (PsA) is associated with a higher burden of co-morbidities such as obesity, cardiovascular disease, non-alcoholic fatty liver disease, inflammatory eye disease, inflammatory bowel disease, skin cancer and depression compared to the general population. In the last 20 years, the therapeutic options for PsA have increased exponentially with the availability of tumor necrosis factor-alpha (TNF) inhibitors, interleukin (IL)-17 inhibitors, IL-12/23 inhibitors and Janus kinases/signal transducer and activator of transcription proteins (JAK/STAT) inhibitors. The articular and extra-articular manifestations of PsA usually dictate the treatment choice but important consideration must be given to the corresponding co-morbidities while deciding the drug therapy due to associated safety profile, effect on disease activity, etc. This review provides a comprehensive review of common co-morbidities in PsA and how they can influence treatment choices.
与普通人群相比，银屑病关节炎（PsA）与肥胖、心血管疾病、非酒精性脂肪性肝病、炎症性眼病、炎症性肠病、皮肤癌和抑郁症等共病负担更高。在过去20年中，随着肿瘤坏死因子-α（TNF）抑制剂、白细胞介素（IL）-17抑制剂、IL-12/23抑制剂和Janus激酶/信号转导和转录激活蛋白（JAK/STAT）抑制剂的出现，PsA的治疗选择呈指数级增加。PsA的关节和关节外表现通常决定治疗选择，但在决定药物治疗时，由于相关的安全性、对疾病活动的影响等，必须充分考虑相应的共病情况。本综述全面回顾了PsA中常见的共病情况以及它们如何影响治疗选择。
